Literature DB >> 11123282

C-C chemokine receptor 4 expression defines a major subset of circulating nonintestinal memory T cells of both Th1 and Th2 potential.

D P Andrew1, N Ruffing, C H Kim, W Miao, H Heath, Y Li, K Murphy, J J Campbell, E C Butcher, L Wu.   

Abstract

CCR4, a chemokine receptor for macrophage-derived chemokine (MDC) and thymus and activation-regulated chemokine (TARC), has been implicated as a preferential marker for Th2 lymphocytes. Following in vitro polarization protocols, most Th2 lymphocytes express CCR4 and respond to its ligands TARC and MDC, whereas Th1 lymphocytes express CXC chemokine receptor 3 and CCR5 (but not CCR4). We show in this study that CCR4 is a major receptor for MDC and TARC on T lymphocytes, as anti-CCR4 mAbs significantly inhibit the migration of these cells to MDC and TARC. CCR4 is also highly expressed in most single-positive CD4(+) thymocytes and on a major fraction of blood nonintestinal (alpha(4)beta(7)(-)) memory CD4 lymphocytes, including almost all skin memory CD4(+) cells expressing the cutaneous lymphocyte Ag (CLA), but weakly or not expressed in other subsets in thymus and blood. Interestingly, major fractions of circulating CCR4(+) memory CD4 lymphocytes coexpress the Th1-associated receptors CXC chemokine receptor 3 and CCR5, suggesting a potential problem in using these markers for Th1 vs Th2 lymphocyte cells. Moreover, although production of Th2 cytokines in blood T cells is associated with CCR4(+) CD4 lymphocytes, significant numbers of freshly isolated circulating CCR4(+) memory CD4 lymphocytes (including both CLA(+) and CLA(-) fractions) readily express the Th1 cytokine IFN-gamma after short-term stimulation. Our results are consistent with a role for CCR4 as a major trafficking receptor for systemic memory T cells, and indicate that the patterns and regulation of chemokine receptor expression in vivo are more complex than indicated by current in vitro models of Th1 vs Th2 cell generation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11123282     DOI: 10.4049/jimmunol.166.1.103

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  54 in total

1.  CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice.

Authors:  Christian Weber; Svenja Meiler; Yvonne Döring; Miriam Koch; Maik Drechsler; Remco T A Megens; Zuzanna Rowinska; Kiril Bidzhekov; Caroline Fecher; Eliana Ribechini; Marc A M J van Zandvoort; Christoph J Binder; Ivett Jelinek; Mihail Hristov; Louis Boon; Steffen Jung; Thomas Korn; Manfred B Lutz; Irmgard Förster; Martin Zenke; Thomas Hieronymus; Tobias Junt; Alma Zernecke
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  CCR4-bearing T cells participate in autoimmune diabetes.

Authors:  Soon H Kim; Mary M Cleary; Howard S Fox; David Chantry; Nora Sarvetnick
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

3.  Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs.

Authors:  Verena Semmling; Veronika Lukacs-Kornek; Christoph A Thaiss; Thomas Quast; Katharina Hochheiser; Ulf Panzer; Jamie Rossjohn; Patrick Perlmutter; Jia Cao; Dale I Godfrey; Paul B Savage; Percy A Knolle; Waldemar Kolanus; Irmgard Förster; Christian Kurts
Journal:  Nat Immunol       Date:  2010-02-28       Impact factor: 25.606

4.  Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma.

Authors:  Naoko Asano; Ritsuro Suzuki; Koichi Ohshima; Yoshitoyo Kagami; Fumihiro Ishida; Tadashi Yoshino; Hiroshi Ogawa; Yasuo Morishima; Shigeo Nakamura
Journal:  Int J Hematol       Date:  2010-03-09       Impact factor: 2.490

5.  CC chemokine receptor 4 contributes to innate NK and chronic stage T helper cell recall responses during Mycobacterium bovis infection.

Authors:  Valerie R Stolberg; Bo-Chin Chiu; Brian M Schmidt; Steven L Kunkel; Matyas Sandor; Stephen W Chensue
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

Review 6.  Chemokines: control of primary and memory T-cell traffic.

Authors:  Patrick Schaerli; Bernhard Moser
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

7.  Production of TARC and MDC by naive T cells in asthmatic patients.

Authors:  Hirokuni Hirata; Masafumi Arima; Gang Cheng; Kyoko Honda; Fumiya Fukushima; Nozomi Yoshida; Fukiko Eda; Takeshi Fukuda
Journal:  J Clin Immunol       Date:  2003-01       Impact factor: 8.317

8.  Expression of the alpha1beta1 integrin, VLA-1, marks a distinct subset of human CD4+ memory T cells.

Authors:  Itamar Goldstein; Shomron Ben-Horin; Jianfeng Li; Ilan Bank; Hong Jiang; Leonard Chess
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

9.  Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.

Authors:  Steffen Walter; Toni Weinschenk; Arnulf Stenzl; Romuald Zdrojowy; Anna Pluzanska; Cezary Szczylik; Michael Staehler; Wolfram Brugger; Pierre-Yves Dietrich; Regina Mendrzyk; Norbert Hilf; Oliver Schoor; Jens Fritsche; Andrea Mahr; Dominik Maurer; Verona Vass; Claudia Trautwein; Peter Lewandrowski; Christian Flohr; Heike Pohla; Janusz J Stanczak; Vincenzo Bronte; Susanna Mandruzzato; Tilo Biedermann; Graham Pawelec; Evelyna Derhovanessian; Hisakazu Yamagishi; Tsuneharu Miki; Fumiya Hongo; Natsuki Takaha; Kosei Hirakawa; Hiroaki Tanaka; Stefan Stevanovic; Jürgen Frisch; Andrea Mayer-Mokler; Alexandra Kirner; Hans-Georg Rammensee; Carsten Reinhardt; Harpreet Singh-Jasuja
Journal:  Nat Med       Date:  2012-07-29       Impact factor: 53.440

10.  Visualizing CD4 T-cell migration into inflamed skin and its inhibition by CCR4/CCR10 blockades using in vivo imaging model.

Authors:  X Wang; M Fujita; R Prado; A Tousson; H-C Hsu; A Schottelius; D R Kelly; P A Yang; Q Wu; J Chen; H Xu; C A Elmets; J D Mountz; C K Edwards
Journal:  Br J Dermatol       Date:  2009-10-15       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.